The nature and origin of microglial cells in the central nervous system (CNS) has been a subject of debate for many decades. del Rio Hortega1 2 was the first to identify cells termed "resting" microglia in normal undamaged CNS and "reactive" or "activated" microglia in traumatic and inflammatory CNS lesions. Intermediate forms also existed, and del Rio Hortega considered that the two forms were interchangeable and were of mesodermal origin. This view has been supported by light and ultrastructural histochemistry.3 Experimental autoradiographic studies have indicated that at least some of the cells with morphological features of activated microglia and macrophages infiltrating CNS lesions are derived from circulating blood mononuclear cells.45 Perivascular adventitial cells also provide a source of phagocytic cells in injured brain parenchyma.6 Some authors have recently questioned the view that resting and activated microglia are derived from blood monocytes; this has arisen because antigens normally expressed by macrophages and blood monocytes are not detectable in resting microglia.457-10 Macrophages, however, are a heterogeneous population, both functionally and in their antigenic properties. The fact that certain macrophage markers have not been detected on resting microglia does not, therefore, conclusively refute their originating from blood monocytes. Furthermore, recent studies on the localisation of the mouse macrophage marker F4/80 in Accepted for publication 23 January 1986 developing and adult mouse brain and retina, which show that F4/80 positive cells migrate into the mouse CNS during development and subsequently differentiate into cells with appearances of resting microglia,"1 12 suggest that these cells may have a macrophage function. The monoclonal antibody EBM/11, raised against lung macrophages, has been shown to react with a cytoplasmic determinant in human macrophages from various organs"3 and other cells of presumptive macrophage origin (E Bliss, unpublished observations). 14 15 In a preliminary survey of undiseased necropsy material EBM/11 reacted with microglial cells in human brain (E Bliss, unpublished observations) . 13 16 This report shows that EBM/ll reacts not only with macrophages but also with microglia in normal and diseased human CNS tissues, indicating that microglial cells and macrophages are phenotypically (and presumably) functionally similar.
Material and methods
Fresh frozen cryostat sections were prepared from surgical and necropsy specimens from the following: normal cerebral cortex and white matter (five cases), brain stem (three cases), and spinal cord (three cases); cerebral gliomas (six cases), meningiomas (two cases), pituitary adenoma (one case), multiple sclerosis plaques and surrounding white matter (five cases), progressive multifocal leucoencephalopathy (one case), acute perivenous leucoencephalitis (one case), 615 616 cerebral infarction (three cases), cerebral granuloma (two cases), acute necrotising encephalitis (one case), and head injury (two cases).
Sections 1Opm thick were mounted on glass slides, fixed in acetone for 10 minutes, washed in 0-15M/I sodium chloride buffered with Tris-hydrochloric acid, pH 7-4 (Tris saline), and covered by the EBM/ 1I antibody, applied as neat ascitic fluid for 30 minutes at 22°C. After washing with Tris saline peroxidase conjugated rabbit antimouse IgG (Dako) (diluted 1/50 with 1/20 normal human serum) was applied to the slides for 30 minutes, washed in Tris saline incubated with diaminobenzidine and H202 for five minutes. Slides were counterstained with haematoxylin. Sections adjacent to those treated with EBM/1 1 antibody were incubated with antibody to glial fibrillary acidic protein anti-GFAP (Monosan). In selected cases double staining was done with EBM/l antibody, using peroxidase labelled second antibody for detection of this antibody and alkaline phosphatase labelled second antibody for detection of anti-GFAP. Immunoreactivity of CNS tissues with EBM/I I antibody was also compared with reactivity to al-antichymotrypsin antiserum (al-ACT) (Dako) (1/1000 dilution), which was detected by using the PAP immunoperoxidase technique on adjacent sections. Results
NORMAL CENTRAL NERVOUS SYSTEM
A regular array of small, bipolar, or multipolar cells Esiri, McGee reactive for EBM/I1 was shown in cerebral white matter (Fig. 1 ). These cells, therefore, had the typical appearances of microglial cells. Nuclei of reactive cells were spaced roughly 30-70pm apart, and their processes in places lay within smaller distances of each other but did not appear to overlap. Similar relatively regular spacing of EBM/11 reactive microglial cells was seen in the white matter of the spinal cord and brain stem and in grey matter of the cerebral cortex. Some of these cells lay close to capillaries and others, in grey matter, close to neurone cell bodies. EBM/l1 reacted with a cytoplasmic component of the positively stained cells, and the reaction product was distinctly granular in appearance. The nuclei of reactive cells both in grey and white matter were small, moderately stained with haematoxylin, oval, or comma shaped, and had stippled chromatin. These small EBM/l1-reactive cells in CNS parenchymal tissues did not react with either the antiserum to ac-ACT or that to GFAP ( Figs. 1 and 2 ). The latter antiserum labels astrocytes, which are larger and have longer smoother processes than microglia (Fig. 2) .
In addition to reacting with the microglial cells described above, EBM/11 reacted with larger cells of polygonal or spindle shape, with abundant cytoplasm found immediately adjacent to parenchymal blood vessels of various types (Fig. 1 ). Similar cells were detected in the leptomeninges where they were also often, but not exclusively, associated with blood vessels (Fig. 3) . The distribution and appearance of these cells suggested that they were macrophages and peri- cytes. Some, but not all of the cells of this type, reacted weakly with the antiserum to a-ACT.
TUMOURS
Cerebral gliomas contained scattered EBM/ 11 positive cells that were larger than those seen in normal brain and had a more rounded outline with fewer processes (Fig. 4) . Their density varied from one part of a tumour to another and from tumour to tumour.
There was an accumulation of EBM/l 1 positive cells at the edge of necrotic areas in glioblastomas (Fig. 5 ). necrotising encephalitis, the cases of cerebral infarction, and the margins of multiple sclerosis plaques reacted strongly with EBM/ 11 (Fig. 8) . The cerebral granulomas also contained numerous intensely reactive spindle and epithelioid type cells. Clusters of reactive microglial cells in the cases of head injury were also easily identified and reacted intensely with EBM/11 (Fig. 9) . Some of the Gitter cells reacted weakly with al-ACT antiserum; the has been diffusely infiltrated rather than destroyed by the tumour. In tumours with extensive necrosis large numbers of additional macrophages were also present, particularly around the necrotic zones. In non-neoplastic cerebral disease strongly positive EBM/1 1 cells were present in large numbers. Results of comparison of these cells with those positive for GFAP generally showed no overlap, but in some cases in which numerous EBM/11 positive cells were present GFAP positive astrocytes also showed a weak diffuse reaction for EBM/l 1. This may result from release of the EBM/1 1 antigen from macrophages and uptake into reactive astrocytes. In general, EBM/l 1 is a sensitive and specific marker for macrophages and microglial cells in the CNS. It reacts with many more cells than does antiserum to a 1-ACT and it shows the normal microglial population more reliably than silver stains. It does, however, require the use of frozen as opposed to formalin fixed material. It is likely to prove a valuable tool in differentiating macrophages and microglial cells from other CNS components and for studying entry of macrophages into the human CNS during development. Our findings using EBM/ 1I support del Rio Hortega's original view that microglia form a part, albeit a specialised part, of the mononuclear phagocyte system.
"Microglioma" and "microgliomatosis" are now presumed to be lymphoreticular malignancies. Fresh tissues from these conditions were not available when this study was done. The reaction of EBM/1 1 in these disorders and cerebral lymphomas will form part of a future study to determine whether any or all of these malignancies express this macrophage marker. 
